NCT03714334终止1 期
Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2018年10月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events after brain administration of DNX-2440.
研究概览
简要总结
Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.
详细描述
After inclusion in the trial, stereotactic biopsy will be performed. In the same surgery, the experimental agent will be injected also by stereotactic system, in a different part of the lesion, in a region considered viable tumor, using a cannula especially designed for virus injection.
Follow-up will include clinical visits and MRI No other treatment for the tumor will be used until progression is documented. iRANO criteria and volumetric measurement of the tumor will be used.
Any further treatment after progression will be at the criteria of the treating physician
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients willing and able to give informed consent.
- •Patient must be, in the investigator opinion, able to comply with all the protocol procedures.
- •Negative pregnant test in case of fertile women*
- •Patients with diagnosis of first or second recurrence of Glioblastoma or any of its variants (Gliosarcoma, Giant cell Glioblastoma or epithelioid Glioblastoma) based on histopathology at first diagnosis and clinical and radiological follow-up. Recurrences within the radiation field will be considered if there is confirmed growing of the lesion in two MRI, or occur at least 12 weeks after completion of radiotherapy, or if there is clear histopathological confirmation of tumor recurrence. This limitation does not apply for recurrences occurring outside the radiation field
- •A single measurable lesion bigger than 10 mm in two perpendicular diameters, considered appropriate for safe stereotactic biopsy and virus injection without entering the ventricle.
- •No other chemotherapy or immunotherapy for the tumor in the four weeks previous to the inclusion
- •Karnofsky Performance Status ≥ 70 before inclusion.
- •Must have adequate renal, bone marrow and liver function.
- •Steroid-free or requiring stable doses of a maximum of 2mg dexamethasone /day or equivalent in the previous two weeks.
- •A woman is considered fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
排除标准
- •Severe infections or intercurrent medical conditions including, but not limited to, severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria, do not allow the inclusion. Patients must be afebrile at baseline [i.e., < 38 degrees (C)].
- •Patients with an enhancing lesion bigger than 25cc, including necrotic tumor portions encircled inside the enhancing areas.
- •Subjects with immunodeficiency, autoimmune conditions or active hepatitis.
- •Any medical or psychological condition that might interfere with the subject's ability to participate or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.
- •Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin. Patients with a history of another cancer remain eligible if they are cancer free for at least three years.
- •Pregnant or breast-feeding females will be excluded, due to the risk for the fetal development of a recombinant virus containing genes related to cellular growth and differentiation.
- •Severe bone marrow hypoplasia.
- •AST and/or ALT > 4 times over upper normal laboratory level
- •Neutrophils < 1.5 x 109/L
- •Thrombocytes ≤ 100 x 109/L
- •Hemoglobin < 9g/dl
- •Multiple lesions, extensive ill-defined diffuse lesions, or lesions considered risky for stereotactic injection of virus, like periventricular lesions.
- •Patients with Li-Fraumeni Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways.
- •Biologic/immunotherapy (e.g., IL-2, IL-12, interferon) within 4 weeks of DNX-2440 administration.
- •Vaccination of any kind within 4 weeks prior to DNX-2440 administration.
- •Inability to undergo MRI examination for any reason.
研究组 & 干预措施
DNX-2440 injection
Experimental
all the patients included will be treated with the experimental agent
干预措施: DNX-2440 injection (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events after brain administration of DNX-2440.
时间窗: 8 weeks
Incidence and severity of adverse effects will be collected and described
次要结局
- Overall response rate (ORR)(6 months)
- Overall Survival at 12 months (OS12)(12 months)
- Overall survival(25 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade GliomaIDH1 wt AlleleRecurrent Anaplastic AstrocytomaRecurrent GlioblastomaRecurrent GliosarcomaRecurrent Malignant GliomaNCT03896568M.D. Anderson Cancer Center36
暂停
1 期
DNX-2440 for Resectable Colorectal Liver MetastasisLiver MetastasesLiver Metastasis Colon CancerPeriampullary CancerRenal Cell CancerGastrointestinal Stromal TumorsBreast CancerGastric CancerMelanomaSarcomaColorectal CancerSquamous Cell CarcinomaNCT04714983DNAtrix, Inc.30
已完成
1 期
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine GliomasBrainstem GliomaNeoadjuvant TherapyNCT03178032Clinica Universidad de Navarra, Universidad de Navarra12
已完成
1 期
Virus DNX2401 and Temozolomide in Recurrent GlioblastomaRecurrent TumorGlioblastoma MultiformeNCT01956734Clinica Universidad de Navarra, Universidad de Navarra31
进行中（未招募）
2 期
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)NCT04567550AbbVie139